Abbott Secures CE Mark for Novel Diabetes Monitoring Solution

Abbott has received CE Mark approval for its Libre Duo and Libre Duo 10 Day systems, becoming the first company to introduce continuous dual glucose and ketone sensing technology for people with diabetes. 

The wearable sensors continuously measure both glucose and ketone levels every minute, giving users real-time information to support daily diabetes management and identify rising ketone levels that may lead to diabetic ketoacidosis. 

The technology removes the need for traditional blood or urine ketone testing and is expected to launch in selected European countries later this year.

The Libre Duo system is designed for adults aged 18 years and above and provides up to 15 days of wear, while Libre Duo 10 Day is intended for people aged two years and older. 

Both devices are designed to deliver accurate readings and integrate with Abbott’s Libre digital health ecosystem, allowing users to share glucose and ketone data with healthcare professionals and caregivers. The company is also working with insulin pump manufacturers to support automated insulin delivery systems.

DKA remains a serious complication of diabetes and can develop rapidly when the body lacks sufficient insulin. Because ketone levels are not routinely monitored and symptoms are often mistaken for common illnesses, early diagnosis is frequently delayed. 

Studies show DKA-related hospital admissions have increased significantly in recent years, highlighting the need for improved monitoring. Continuous ketone monitoring is also supported by recent international expert recommendations as an important step towards enhancing diabetes care and reducing the risk of severe complications. 

The Libre Duo systems are currently approved for Europe but are not yet available in the United States.